Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 19,799,000 | 19,291,500 | 17,600,800 | 15,557,700 | 12,729,000 |
| Cost of Goods | 3,577,000 | 3,370,900 | 3,008,300 | 2,447,800 | 2,225,000 |
| Gross Profit | 16,222,000 | 15,920,600 | 14,592,500 | 13,109,900 | 10,504,000 |
| Operating Expenses | 7,307,000 | 7,547,000 | 7,227,300 | 6,243,700 | 6,809,000 |
| Operating Income | 8,915,000 | 8,374,500 | 7,365,500 | 6,867,000 | 3,695,000 |
| Other Income | -65,000 | -108,301 | -133,100 | -90,600 | -239,000 |
| Pre-tax Income | 8,850,000 | 8,266,199 | 7,232,400 | 6,776,400 | 3,456,000 |
| Income Tax | 1,454,000 | 1,628,200 | 1,649,900 | 1,115,900 | 697,000 |
| Net Income Continuous | 7,396,000 | 6,638,000 | 5,582,500 | 5,660,500 | 2,759,000 |
| Net Income | $7,396,000 | $6,638,000 | $5,582,500 | $5,660,500 | $2,759,000 |
| EPS Basic Total Ops | 8.27 | 7.41 | 6.22 | 6.30 | 3.07 |
| EPS Basic Continuous Ops | 8.27 | 7.40 | 6.22 | 6.30 | 3.07 |
| EPS Diluted Total Ops | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 |
| EPS Diluted Continuous Ops | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 |
| EPS Diluted Before Non-Recurring Items | N/A | 7.54 | 7.02 | 6.31 | 3.34 |
| EBITDA(a) | $9,424,000 | $8,960,200 | $7,835,500 | $7,345,300 | $4,158,000 |